The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs

New antiviral drugs are needed for the treatment of cytomegalovirus (CMV) infections, particularly in immunocompromised patients. These studies evaluated the in vitro and in vivo activity of the non-nucleosidic CMV inhibitor, BAY 38-4766, against guinea pig cytomegalovirus (GPCMV). Plaque reduction...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Schleiss, Mark R., Bernstein, David I., McVoy, Michael A., Stroup, Greg, Bravo, Fernando, Creasy, Blaine, McGregor, Alistair, Henninger, Kristin, Hallenberger, Sabine
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2005
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2768478/
https://ncbi.nlm.nih.gov/pubmed/15652969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.antiviral.2004.09.004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak